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Background: Locally advanced breast cancer (LABC) is still common in developing countries. The asso-
ciation between neoadjuvant chemotherapy (NC) and oncoplastic surgery (OS) might provide an onco-
logical treatment with satisfactory aesthetic results.
Purpose: The goal was to demonstrate if oncoplastic surgical techniques can be utilized to treat LABC
which was submitted to neoadjuvant chemotherapy.
Methods: This prospective clinical trial included breast cancer patients, clinical stage III, who underwent
established NC regimen. All patients underwent preoperative planning to control the tumor size and to
deﬁne the surgical technique. A detailed analysis of the pathological specimen was performed.
Results: 50 patients were assessed and surgically treated. Tumor size ranged from 3.0 to 14.0 cm (median
6.5 cm). Pathologic response was rated as stable, progressive, partial response, and complete response in
10%, 8%, 80% and 2% of the cases, respectively. Seventeen (34%) patients were submitted to OS. No patient
had positive margins. Skin involvement was presented in 36% of pathologic specimen.
Conclusions: Oncoplastic surgical techniques for selected patients decrease the rates of radical surgery
despite large tumors. (www.clinicaltrials.gov, NCT00820690).
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The incidence of locally advanced breast cancer (LABC) remains
high1 and requires special attention in developing countries. Non-
metastatic LABC comprises tumors greater than 5 cm in diameter
or that involve skin or chest wall.2
Historically, LABC was treated by radical surgery.3 Progression of
studies over time favored systemic therapy along with locoregional
treatment.
The use of neoadjuvant chemotherapy (NC) allows the early
initiation of systemic therapy, delivery of drugs through intacter; NC, neoadjuvant chemo-
ing treatment; AP, anatomo-
M, skin-sparing mastectomy;
asound; MRI, magnetic reso-
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ciates Ltd. Published by Elsevier Ltvasculature, in vivo assessment of response to therapy, and the
possibility of breast-conserving surgery in a selected number of
patients. On the other hand, its disadvantages are delayed local
treatment, potential drug resistance, poorer response in large
tumors, and the possibility of higher surgical risk.4
Over time, surgical techniques have advanced to the point
where breast-conserving therapy (BCT) has become the standard
form of treatment for early stage breast carcinomas.5,6 By the early
90’s Audretsch7 suggested the use of plastic surgery techniques
for the immediate breast cancer treatment. Conceptually, this
approach referred to as “oncoplastic surgery”, aims at providing
safe oncologic treatment through careful pre-operative planning
and the incorporation of plastic surgery techniques in order to
obtain good oncologic control. Moreover, oncoplastic surgery (OS)
very often offers improved overall aesthetic outcomes and favors
the achievement of contralateral breast symmetry.8,9
In the same way, the mastectomy has changed and Toth &
Lappert10 described the technique of skin-sparing mastectomy
(SSM) in association with the removal of malignant tumors. That
enabled the maintenance of a large part of the skin and infra-
mammary fold facilitating immediate breast reconstruction.11d. All rights reserved.
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there are few studies regarding skin-sparing mastectomies and
local advanced breast cancer.12,13
The purpose of this study was to demonstrate if oncoplastic
surgical techniques can be utilized to treat LABC which was
submitted to neoadjuvant chemotherapy. The focus was on the
possibility of preserving breast shape, particularly using onco-
plastic surgical techniques, including immediate breast recon-
struction with implants after skin-sparing mastectomy. Therefore,
a descriptive analysis of pathologic ﬁndings and surgical options
was fundamental to the conclusions.
2. Patients and methods
This prospective clinical study was conducted between June/2008 and
December/2009, including women with LABC, stage III, no clinical diffuse skin
involvement, ECOG 0 or 1, and a conﬁrmed diagnosis of inﬁltrating ductal or lobular
carcinoma.
Exclusion criteria were pregnancy, primary or secondary inﬂammatory carci-
nomas, ulcerated tumors, atypical histology, and patient unavailability to undergo
all exams.
2.1. Ethics
The study was approved by the local Committee of Research Ethics (135/2008
and 210/2009) and registered on www.clinicaltrials.gov, NCT00820690. Written
informed consent was obtained from all subjects.
2.2. Clinical and radiological assessment
Staging was determined by exams. Diagnosis was conﬁrmed by a previous
biopsy. Preoperative physical exam (PE) tumor measurements were correlated with
mammography (MG), breast ultrasound (US) and magnetic ressonance (MRI).
Postoperatively pathologic ﬁndings were also correlated with PE, MG, US and MRI.
Only the larger diameters were considered. Tumors were measured pre- and post-Fig. 1. Sequence of pathological exam: (a) Ink-marked tumor before neoadjuvant chemot
Multiple foci of residual single cells or small clusters in the midst of extensive ﬁbrosis (100operatively using a caliper and Pixer Viewer software version 3.315.R. Physical
examination was considered as the gold standard for comparison with pre-
chemotherapy radiologic exams as well as anatomopathologic examination (AP)
for post-chemotherapy ones (Fig. 1).
Neoadjuvant chemotherapy, consisting of 4 cycles of doxorubicin 60
mg/m2 þ cyclophosphamide 600 mg/m2 (4AC) followed by 4 cycles of paclitaxel
175 mg/m2 (4T).
Pre-therapy, eligibility for any oncoplastic surgical technique to be used were
assessed. After chemotherapy, these same aspects were reassessed. Assessments
were mostly based on the relation between tumor size and breast volume.
Non-conserving surgeries consisted of radical and modiﬁed radical mastectomy.
While in this study the oncoplastic surgical techniques included the use of periar-
eolar, superior and inferior pedicle techniques, quadrantectomy with glandular
remodeling, dermo-glandular ﬂaps and immediate breast reconstruction with
implant after skin-sparing mastectomies.
At the time of diagnostic biopsy, tumor borders were ink-marked on the
patient’s skin. Oncoplastic surgical treatment was chosen based on tumor size,
breast volume, resection of the marked area, obtaining a surgical free margin,
comorbidities, and patient desire. All patients underwent axillary lymph node
dissection and adjuvant therapy, including radiotherapy assessment.
Patients were followed up from admission up to their last appointment. If
a patient did not return for appointments in a period more than twice longer than
expected, such individual was deemed lost to follow up.
2.3. Pathological assessment
Surgical specimens were identiﬁed according to their topography and spatial
position (Fig. 2a). Perioperatively, an experienced pathologist assessed the surgical
margins on frozen section (Fig. 2b). In-depth gross and microscopic examinations
were performed. All specimens including the skin ink-marked areas of primary
neoplasia were completely sectioned for microscopic examination so that residual
tumor size could be measured even when it could not be well determined grossly
(Fig. 2c). For anatomo-pathologic response assessment, tumoral as well as eventual
ﬁbrotic areas, presence of residual disease, macroscopic (residual nidus over small
areas) and microscopic (residual scatter cells over original volume) disease foci were
evaluated (Fig. 2d).
Final pathologic measurement was based on total tumor size, i.e., the sum of
invasive plus non-invasive disease, if present. In cases of complete pathologicherapy; (b). pathologic specimen; (c) gross assessment; (d) microscopic assessment:
 e hematoxylin-eosin).
Fig. 2. Different techniques performed: (a) Quadrantectomy with glandular remod-
eling; (b and c) Locoregional rotational ﬂap; (d) Plug ﬂap associated to contralateral
symmetrization; (e) Skin-sparing mastectomy using implant and contralateral
symmetrization; (f) Left upper quadrantectomy using oncoplastic lower pedicle
technique.
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mates were used. If the margins were free, conservative treatment was maintained.
On the other hand, when margins were considered small on gross analysis, margin
re-excision or classic mastectomy was performed.
2.4. Statistical analysis
A descriptive analysis of the results was carried out. The chi-squared test was
performed to verify the relationship among variables and skin involvement. Then
logistic regressionwas used to calculate the odds ratio and certify the results relatedto the skin involvement. Statistical analysis was performed using Statistical Package
for Social Science e SPSS for Windows version 17.0.
3. Results
Over 21 months, 50 patients were assessed and surgically
treated. Patient median age was 45 years (21e65 years). The
majority of the cases showed inﬁltrating ductal carcinoma (92%)
while 8% had inﬁltrating lobular carcinomas (Table 1). Tumor size
ranged from 3 to 14 cm (mean size¼ 6.7 cm, median size¼ 6.5 cm).
Table 2 shows case distribution according to clinical stage (CS) III-
TNM and tumor site.
Surgical planning was based on physical examination and
imaging techniques prior and after chemotherapy, and also on post-
chemotherapy response.
After chemotherapy 17 (34%) of patients were eligible to be
operated and actually received some kind of oncoplastic surgical
treatment (Table 3, Fig. 2). Of those, 5 (10%) underwent some kind
of glandular remodeling for correction of acquired defect, 08 (16%)
had skin-sparingmastectomy (SSM), 01 (2%) superior pedicle, and 2
(4%) inferior pedicle, and 1 (2%) underwent rotation of a dermo-
glandular ﬂap.
Classic mastectomy was performed in 66% of the patients, and
Halsted radical mastectomy in only one case (2%).
The rates of complete clinical, radiologic, and pathological
responses were 20% (in 10 patients), 6% (3 patients), and only 2% (1
patients), respectively. All patients showed tumor-negative
margins. Table 3 shows the characteristics of the patients under-
going oncoplastic surgery, and examples are provided in Fig. 2. All
women receiving conserving treatment had negative margins.
Pathologic responses were classiﬁed as stable, progressive,
partial and complete in 10%, 8%, 80% and 2% of the cases, respec-
tively. A great variety of pathologic responses was observed.
Concentric decrease in tumor size was the most frequent ﬁnding
(46%), followed by tumor microfragmentation (14%), and macro-
fragmentation with multiple foci (12%) (Table 4).
Skin involvement was presented in 36% of pathologic specimen
regardless previous clinical exam. The relation between tumor size
and skin involvement was statistically signiﬁcant. Comparing
tumor size before (p ¼ 0.01) and after (p ¼ 0.009) the NC, the
logistic regression showed that the previous measurement is
a better predictor for skin involvement. The tumor size-
> or¼ 6.5 cm before NC has showed approximately ﬁve timesmore
chance of skin involvement, odds ratio ¼ 4.964 (C.I. ¼ 1.40e17.55).
4. Discussion
Neoadjuvant chemotherapy (NC) was introduced as a treatment
for breast cancer in the 70 s. Since then, the rate of conserving
surgeries has increased, even in LABC cases. Although objective
responses to LABC systemic treatment ranging from 60% to 85%
have been demonstrated in several studies,14e16 there is still no
consensus about breast conserving LABC treatment after NC.
The lack of uniform methods has led some authors17,18 to asso-
ciate LABC with poor prognosis. For some authors, the diversity of
pathologic ﬁndings indicates the need for mastectomy.15,19
However, the low recurrence rates reported in selected cases of
T3 and T4 shows that these patients could have undergone
conserving surgery.20,21 Nonetheless, given that data on conserving
treatment for T3 (>5 cm) and T4 tumors are still scarce, complete
skin removal was performed in our cases of focal disease. In addi-
tion, whenever the extension of the skin edema was uncertain,
classic mastectomy was carried out. The skin involvement stimu-
late a particular attention to this. 36% of involvement regardless the
clinical examination and a better correlation with the tumor size
Table 1
Proﬁle of the tumors submitted to OS and observed in this series.
Case Histologic
type
ER PgR HER-2 Nuclear
grade
Angio-lymphatic
invasion
Intraductal
carcinoma associated
Final AP tumor
size(cm)
Number of
dissecated lymph nodes
Number of positive
lymph node
1 IDC þ e þþþ III No No 1 22 0
2 IDC e e þþþ III Missing Missing 2 19 0
3 IDC þ þ þþþ II No No 1.5 26 3
4 IDC þ þ þþþ III Missing Missing 6 23 7
5 ILC þ þ þþþ I No Yes 5.5 20 2
6 IDC þ þ þþþ II No No 0.6 28 6
7 IDC þ þ e II Yes No 6.5 18 1
8 IDC þ e þþþ III No No 3.5 6 0
9 IDC þ þ e III No No 6 7 0
10 IDC þ þ þþþ II Yes No 2.2 14 4
11 IDC þ þ þþþ III No No 1.5 21 15
12 IDC þ þ e III No No 8.3 22 0
13 IDC þ e e III Yes Missing 0 27 0
14 IDC e þ e II No No 4.4 1* 0
15 IDC þ þ e III No No 3 31 0
16 IDC þ þ þþþ II No No 1.2 21 0
17 IDC e e e III No No 4.2 24 0
IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; ER: estrogen receptor; PgR: progesterone receptor; * sentinel lymph node biopsy.
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after NC. This decision can affect the aesthetic result.
Poor aesthetic results were an impediment to BCT in LABC.22 The
integration of oncoplastic surgical techniques has allowed more
extensive resections through alternative incisions that enable the
dissection of larger breast volume with good cosmetic results.7,8
Relatively simple oncoplastic surgical techniques can greatly
improve cosmetic outcomes by reshaping the gland after
quadrantectomy.23,24
This study aimed at associating NC response with oncoplastic
surgical techniques in an attempt to provide safe surgical treatment
for LABC. No prospective controlled trial has addressed this issue as
suggested byMathewet al.,25 but these approaches can certainly be
used to resect large-volume tumors, including skin. Regaño et al.
treated 23 patients with oncoplastic surgery after NC.26 Kaur et al.27
demonstrated that oncoplastic techniques allowed removing
a larger volume of breast tissue and obtaining wider margins in T1-
T2 tumors. Furthermore Clough et al.8 mentioned new incision
options to resect larger tumors with oncologic safe margins.
According to some investigators, BCT should be indicated only
when patients have resolution of any skin changes, absence of
multifocal or multicentric disease, and residual tumor < 4 cm28 or
5 cm.20 However, studies addressing this issue are necessary.Table 2
Case distribution according to clinical stage (CS) III- TNM and tumor site.
Variable Category N patients (%)
CS III IIIa 32 64
IIIb 14 28
IIIc 4 8
CS T-TNM T2 1 2
T3 33 66
T4b 16 32
CS N-TNM N0 2 4
N1 35 70
N2 10 20
N3 3 6
Breast side Left 27 54
Right 20 40
Bilateral 3 6
Topography Outer UQ 15 30
Central Q 10 20
UpperQQ 9 18
Medial LQ 4 8
Lateral QQ 4 8
Other 8 16
Total 50 100.0Among our cases, oncoplastic surgeries were indicated when
the pathology demonstrated concentric decrease in tumor volume
(52.9%), tumor microfragmentation (17.6%), or complete response
with tumor absence (5.9%). In these cases of complete pathologic
response, clinical and radiologic responses were partial. LABC
response to NC is probably induced by a process of tumor
segmentation, and is associated with an increased incidence of
multifocality and intraductal carcinomas.
Most usually, patients who receive NC have less breast tissue
excised. Still, there is a lack of controlled studies assessing patho-
logical response following thecomplete excisionof theoriginal tumor
area. In our patients, total excisionwasmade possible by ink-marking
the tumor skin projection preoperatively as suggested by Mathieu
et al.29 In addition, imaging methods were also used to determine
eligibility for surgery. It is noteworthy that skin tattooing permitted
localizing the tumor area, which was completely removed, irre-
spective of the clinical-radiologic response. Thus, the quality of the
measuring procedures and pathologic assessment was assured. The
low rate of complete response obtained is due to a more thorough
pathologic examination of the specimen regarding that we consid-
ered the entire volume of the tumor at pre-operative assessment.
Given that LABC requires the removal of extensive areas viewing
oncologic safety, mastering oncoplastic surgical techniques are
important to achieve optimal and safe results. Oncoplastic surgical
techniques, in turn, certainly permit the excision of the entire
preoperatively ink-marked tumor area regardless of tumor response.
As they include the complete removal of the skin and parenchyma as
well as any resulting lesions such as microfragmentation. The expe-
rienceof the surgeons30wasessential in the indication foroncoplastic
surgery in 34% of our cases. Although this subjective criterion cannot
be expressed in numbers, it should certainly be taken into account.Table 3
Tumor characteristics in patients receiving oncoplastic techniques and type of
surgery performed.
Anatomopathologic ﬁndings No (%)
Concentric decrease 22 (44%)
Macrofragmentation with multiple macroscopic tumors 6 (12%)
Tumor microfragmentation 7 (14%)
Stable disease 5 (10%)
Macro and microfragmentation with in situ carcinoma 3 (6%)
in situ carcinoma 1 (2%)
Tumor absent 2 (4%)
Disease progression 4 (8%)
Total 50 (100.0%)
Table 4
Macroscopic and microscopic anatomopathologic ﬁndings.
Case CS-T
TNM
Size pre-CT
PE (cm)
CS-N TNM Pre-CT assessment CT AP response Size post-CT
PE (cm)
Size AP (cm) Surgery type
1 T3 5.2 N1 Favorable breast/tumor Tumor microfragmentation 0 1 Quadrantectomy/remodeling
2 T3 5.4 N1 Favorable breast/tumor Tumor microfragmentation 0 2 Upper pedicle technique
3 T3 5.5 N1 Favorable breast/tumor Macrofragmentation and
microfragmentation with
intraductal carcinoma
1.8 1.5 SSMa
4 T3 6 N1 Favorable breast/tumor Stable 2.5 6 Lower pedicle technique
5 T3 6 N1 Favorable breast/tumor Concentric decrease 2.5 5.5 SSM
6 T3 6 N1 Favorable breast/tumor Concentric decrease 2 0.6 SSM
7 T3 6.5 N1 Favorable breast/tumor Macrofragmentation with
multiple tumors
4 6.5 SSM
8 T3 7 N1 Favorable breast/tumor Concentric decrease 2.4 3.5 Quadrantectomy/remodeling
9 T3 7 N1 Favorable breast/tumor Concentric decrease 3 6 SSM
10 T3 7 N1 Favorable breast/tumor Concentric decrease 4.3 2.2 Quadrantectomy/remodeling
11 T3 7.8 N1 Favorable breast/tumor Concentric decrease 5 1.5 Quadrantectomy/remodeling
12 T3 9 N2 Not eligible Macrofragmentation and
microfragmentation with
intraductal carcinoma
3 8.3 Lower pedicle technique
13 T4b 3 N1 Favorable breast/tumor Complete 1.8 0 Quadrantectomy/skin
glandular ﬂap
14 T4b 4 N0 Favorable breast/tumor Concentric decrease 2.1 4.4 SSM
15 T4b 5.5 N2 Favorable breast/tumor Tumor microfragmentation 2.7 3 SSM
16 T4b 5.5 N1 PT4 allowed BCT Concentric decrease 3.5 1.2 Quadrantectomy/remodeling
17 T4b 6.5 N2 pT4 allowed BCT Concentric decrease 3.5 4.2 SSM
a SSM: Skin-sparing mastectomy.
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the concept of SSM and immediate breast reconstruction.10 Often
SSM involves subcutaneous mastectomy and/or contralateral
mastopexy to achieve symmetrization, and therefore, has also been
called oncoplastic mastectomy.31 It provides excellent cosmetic
outcome while being oncologically safe. Furthermore there is no
consensus about the following radiotherapy treatment and there
are few studies regarding skin sparing mastectomies and local
advanced breast cancer.12,13 Woosung et al. demonstrated that SSM
after breast reconstruction is oncologically safe for LABC. There was
no difference in local recurrence rates between SSM and conven-
tional mastectomies. Only 56.3% of their cases received post-
operative radiotherapy.32
The problems about the assessment tool depend on patient
desire and surgeon experience. So the assessment can be imprecise
and it can explain the decrease of indications after chemotherapy.
All patients were thoroughly informed about the risk of compli-
cations, and poor aesthetic outcomes that could result from the
association with radiotherapy.33
This study did not focus on the prognostic relationship among
ﬁndings, but it clearly showed that the variety of pathologic
responses seen indicate that the entire pre-chemotherapy tumor
area should be removed, and that oncoplastic surgical techniques
were a useful approach.
That being said, one might ask the following question: given
that the present investigation aimed at removing the pre-
chemotherapy tumor area, and plastic surgery techniques allow
removing all the marked area with good cosmesis, why administer
NC instead of removing the primary tumor? The answer is not quite
simple. Despite all controversy regarding neoadjuvant and adju-
vant therapies, primary therapy is known to enable assessment of
in vivo tumor response, decrease the load of micrometastatic
disease and reduce tumor size allowing its removal with safer
margins,34 as well as a better control of locoregional recurrence.
Even though NC does not improve overall survival (OS) or disease-
free survival (DFS),25,35 it may offer signiﬁcant psychological
beneﬁts36,37 as well as the primary surgery. Recently Le Ray I et al.
suggested that the use of neoadjuvant therapy in clinical practice
should be carefully discussed before implementation to take intoaccount the beneﬁts and risks for the patient. Quality of life could
be the cornerstone of this discussion.38
Therefore, careful consideration should be given to the use of
conserving surgery, especially in LABC cases. Each case should be
assessed individually combining clinical and imaging examinations
which allows a good surgical planning to add oncoplastic surgical
techniques to completely remove the pre-chemotherapy tumor.
5. Conclusions
The use of NC with oncoplastic surgical techniques for the
treatment of selected LABC patientsmight be a good option to avoid
radical surgery. It allows removing the entire area supposedly
affected with safety and favorable cosmetic outcomes. A detailed
pathologic analysis of a deﬁned tumoral area improves the rates of
ﬁndings. Follow-up data are essential to establish the oncologic and
aesthetic efﬁcacy of this treatment modality in the future.
Ethical approval
This paper mention an educational experience so it is not
necessary for an Ethical Approval.
Funding
No source of funding for our research.
Author contribution
AGZ Matthes and RAC Vieira: study design, data analysis and
writing.
Others: data collection.
Conﬂict of interest
No conﬂict of interests.
Acknowledgments
The authors are grateful to the Researchers Support Centers
from both HCB and School of Medicine of Botucatu-UNESP. We also
appreciate the cooperation of all colleagues in the Department of
Mastology e HCB.
A.G. Zucca Matthes et al. / International Journal of Surgery 10 (2012) 500e505 505
ORIGINAL RESEARCHA special thank to Dr James Hurley and Wilson Marçal for
proofreading the manuscript.References
1. Schwartsmann G. Breast cancer in South America: challenges to improve early
detection and medical management of a public health problem. J Clin Oncol
2001;19:118Se24S.
2. Sobin LHWC. UICC: TNM classiﬁcation of malignant tumors 2002.
3. Halsted WSI. The results of operations for the cure of cancer of the breast
performed at the Johns Hopkins hospital from June, 1889, to January, 1894. Ann
Surg 1894;20:497e555.
4. Liu SV, Melstrom L, Yao K, Russell CA, Sener SF. Neoadjuvant therapy for breast
cancer. J Surg Oncol 2010;101:283e91.
5. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al.
Twenty-year follow-up of a randomized trial comparing total mastectomy,
lumpectomy, and lumpectomy plus irradiation for the treatment of invasive
breast cancer. N Engl J Med 2002;347:1233e41.
6. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-
year follow-up of a randomized study comparing breast-conserving surgery
with radical mastectomy for early breast cancer. N Engl J Med
2002;347:1227e32.
7. Audretsch WP, Rezai M, Kolotas C, Zamboglou N, Schnabel T, Bojar H. Onco-
plastic surgery: "Target" volume reduction (BCT-mastopexy), lumpectomy,
reconstruction (BCT-reconstruction), and ﬂap-supported operability in breast
cancer. Second European congress on senology. Breast Dis 1994:139e57.
8. Clough KB, Lewis Jacqueline S, Couturaud Benoit, Fitoussi Alfred, Nos Claude,
Falcou Marie-Christine. Oncoplastic techniques allow extensive resections for
breast-conserving therapy of breast carcinomas. Ann Surg 2003;237:9.
9. Matthes AGZ, Rietjens M, Brenelli FP, Vieira MAC. Cirurgia oncoplástica: uma
reﬁnada alternativa para o tratamento contra o câncer de mama. Rev Soc Bras
Canc 2006;2:40e8.
10. Toth BA, Lappert P. Modiﬁed skin incisions for mastectomy: the need for plastic
surgical input in preoperative planning. Plast Reconstr Surg 1991;87:1048e53.
11. Lebovic GSLD, Berkowitz RL. Aesthetic approach to simple and modiﬁed radical
mastectomy. Contemp Surg 1994;45:15e9.
12. Davies K, Allan L, Roblin P, Ross D, Farhadi J. Factors affecting post-operative
complications following skin sparing mastectomy with immediate breast
reconstruction. Breast 2011;20:21e5.
13. Sheikh F, Rebecca A, Pockaj B, Wasif N, McCullough AE, Casey W, et al. Inad-
equate margins of excision when undergoing mastectomy for breast cancer:
which patients are at risk? Ann Surg Oncol 2011;18:952e6.
14. Hortobagyi GN, Buzdar AU. Management of locally advanced breast cancer. Am
J Clin Oncol 1988;11:597e601.
15. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation
surgery after induction chemotherapy for locally advanced breast carcinoma.
Cancer 1992;69:2849e52.
16. Schwartz GF, Birchansky CA, Komarnicky LT, Mansﬁeld CM, Cantor RI,
Biermann WA, et al. Induction chemotherapy followed by breast conservation
for locally advanced carcinoma of the breast. Cancer 1994;73:362e9.
17. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al.
Measurement of residual breast cancer burden to predict survival after neo-
adjuvant chemotherapy. J Clin Oncol 2007;25:4414e22.
18. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Outlaw ED, Strom EA, et al.
Breast conservation after neoadjuvant chemotherapy. Cancer 2005;103:689e95.
19. Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, et al. Evaluation
of neoadjuvant chemotherapeutic response of locally advanced breast cancer
by magnetic resonance imaging. Cancer 1996;78:91e100.20. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED,
et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson
cancer center experience. J Clin Oncol 2004;22:2303e12.
21. Gentilini O, Intra M, Gandini S, Peruzzotti G, Winnikow E, Luini A, et al. Ipsi-
lateral breast tumor reappearance in patients treated with conservative
surgery after primary chemotherapy. The role of surgical margins on outcome.
J Surg Oncol 2006;94:375e9.
22. Hery M, Namer M, Moro M, Boublil JL, LaLanne CM. Conservative treatment
(chemotherapy/radiotherapy) of locally advanced breast cancer. Cancer
1986;57:1744e9.
23. Anderson BO, Masetti R, Silverstein MJ. Oncoplastic approaches to partial
mastectomy: an overview of volume-displacement techniques. Lancet Oncol
2005;6:145e57.
24. Petit JY, De Lorenzi F, Rietjens M, Intra M, Martella S, Garusi C, et al. Technical
tricks to improve the cosmetic results of breast-conserving treatment. Breast
2007;16:13e6.
25. Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JF. Neo-
adjuvant chemotherapy for locally advanced breast cancer: a review of the
literature and future directions. Eur J Surg Oncol 2009;35:113e22.
26. Regano S, Hernanz F, Ortega E, Redondo-Figuero C, Gomez-Fleitas M. Onco-
plastic techniques extend breast-conserving surgery to patients with neo-
adjuvant chemotherapy response unﬁt for conventional techniques. World J
Surg 2009;33:2082e6.
27. Kaur N, Petit JY, Rietjens M, Mafﬁni F, Luini A, Gatti G, et al. Comparative study
of surgical margins in oncoplastic surgery and quadrantectomy in breast
cancer. Ann Surg Oncol 2005;12:539e45.
28. Singletary SE. Neoadjuvant chemotherapy in the treatment of stage II and III
breast cancer. Am J Surg 2001;182:341e6.
29. Mathieu MC, Bonhomme-Faivre L, Rouzier R, Seiller M, Barreau-Pouhaer L,
Travagli JP. Tattooing breast cancers treated with neoadjuvant chemotherapy.
Ann Surg Oncol 2007;14:2233e8.
30. Vieira RACZ-MAG, Michelli RAD, Ribeiro GFP, Mendonça MLH, Bailao Jr A,
Haikel LR, et al. Oncoplastic surgery and breast surgeon training. Rev Bras
Mastol 2010;20:66e70.
31. Lebovic GS. Oncoplastic surgery: a creative approach to breast cancer
management. Surg Oncol Clin N Am 2010;19:567e80.
32. Lim W, Ko BS, Kim HJ, Lee JW, Eom JS, Son BH, et al. Oncological safety of skin
sparing mastectomy followed by immediate reconstruction for locally
advanced breast cancer. J Surg Oncol 2010;102:39e42.
33. Mokbel R, Mokbel K. Skin-sparing mastectomy and radiotherapy: an update.
Int Semin Surg Oncol 2006;3:35.
34. Newman LA, Buzdar AU, Singletary SE, Kuerer HM, Buchholz T, Ames FC, et al.
A prospective trial of preoperative chemotherapy in resectable breast cancer:
predictors of breast-conservation therapy feasibility. Ann Surg Oncol
2002;9:228e34.
35. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic
treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188e94.
36. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P,
et al. Recommendations from an international expert panel on the use of
neoadjuvant (primary) systemic treatment of operable breast cancer: an
update. J Clin Oncol 2006;24:1940e9.
37. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al.
Effect of preoperative chemotherapy on local-regional disease in women with
operable breast cancer: ﬁndings from national surgical adjuvant breast and
bowel project B-18. J Clin Oncol 1997;15:2483e93.
38. Le Ray I, Dabakuyo S, Crehange G, Bardou M, Arnould L, Fraisse J, et al. Neo-
adjuvant therapy for breast cancer has no beneﬁts on overall survival or on the
mastectomy rate in routine clinical practice. A population-based study with
a median follow-up of 11years using propensity score matching. Eur J Cancer
2012.
